ReviewACS omega2026
Bridging the Resolution Gap in Recurrent Prostate Cancer Imaging: Quantum Dots as PSMA-Targeted Optical Probes.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent prostate cancer (RPC) remains a major clinical challenge driven by residual and disseminated tumor cells exhibiting pronounced molecular and spatial heterogeneity. Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography enables sensitive whole-body detection of recurrent lesions; however, its millimeter-scale spatial resolution and limited multiplexing capacity constrain the characterization of cellular heterogeneity and micrometastatic disease. Quantum dots (QDs) are nanoscale optical probes with high brightness, exceptional photostability, and narrow, size-tunable emission spectra, enabling multiplexed molecular imaging at subcellular resolution. When functionalized with PSMA-targeting ligands, QDs facilitate the sensitive and spatially resolved visualization of PSMA expression, supporting the detection of heterogeneous and low-abundance tumor cell populations. Among QD platforms, cadmium-based systems offer superior optical performance for multiplexed imaging, whereas cadmium-free and carbon-based QDs provide improved biocompatibility and greater translational potential. Nevertheless, challenges related to toxicity, biodistribution, and clearance remain significant barriers to clinical application. This Review highlights QDs as complementary optical probes that may bridge the resolution gap between whole-body imaging and cellular-scale analysis, with particular relevance for preclinical research, ex vivo tissue interrogation, and intraoperative imaging. Collectively, QD-based strategies provide a conceptual framework for enhancing molecularly specific, high-resolution visualization in RPC imaging workflows.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.